Vimarsana
Biggest News Aggregation in the World

Page 27 - Science Summit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Science Summit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Science Summit Today - Breaking & Trending Today

Dr Vaishampayan on the Impact of TKI Combination Therapies in the Treatment of RCC - Vimarsana News

Dr Vaishampayan on the Impact of TKI Combination Therapies in the Treatment of RCC

Ulka Nitin Vaishampayan, MBBS, discusses updated data for frontline TKI combination therapies in the treatment of patients with metastatic renal cell carcinoma.

Manana Discusses Systemic Racism in Oncology and Future Steps for Equitable Cancer Care - Vimarsana News

Manana Discusses Systemic Racism in Oncology and Future Steps for Equitable Cancer Care

Dr Manana discusses how systemic racism appears in oncology practice, tools clinicians can use to learn about and address their implicit biases, and the importance of connecting patients with a multidisciplinary team to provide necessary resources and care.

Reuss Reviews the Development of LP-300 in Advanced NSCLC - Vimarsana News

Reuss Reviews the Development of LP-300 in Advanced NSCLC

Dr Reuss discusses the development of LP-300 in advanced NSCLC, the mechanisms of LP-300 that may help synergize with the activity of platinum-based chemotherapy, and its ongoing investigation in the phase 2 HARMONIC trial.

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC - Vimarsana News

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Dr Armstrong discusses the FDA approval of olaparib plus abiraterone in patients with BRCA-mutated mCRPC, key efficacy and safety data from the PROpel trial, and where the field of prostate cancer research may be headed in the future.

FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL - Vimarsana News

FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL

Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-1 trial, and the potential future of bispecific antibodies in this setting.